INLIF (NASDAQ:INLF) is a digital health company that designs and commercializes wearable medical devices and software platforms for continuous patient monitoring. Its flagship product, the InLifePRO wearable sensor, captures cardiac and respiratory data in real time, while the InLif Analytics Suite applies AI-driven algorithms to deliver actionable health insights. These integrated solutions support early detection of chronic conditions and help reduce hospital readmissions by enabling remote oversight of at-risk patients.
In addition to its device offerings, INLIF provides a cloud-based remote patient monitoring service that streamlines data collection, alert management, and reporting for healthcare providers. Through secure portals, clinicians can track patient adherence, review automated alerts, and generate customized care plans. This service is designed to improve clinical outcomes, enhance patient engagement, and optimize operational efficiency in both hospital and home-care settings.
Founded in 2016 and headquartered in Seattle, Washington, INLIF has extended its global footprint with research and development centers in Boston, Massachusetts, and Munich, Germany. The company maintains strategic partnerships with leading medical institutions, technology firms, and distributor networks across North America and Europe. These collaborations have accelerated product validation, regulatory approvals, and market expansion.
Led by CEO Dr. Emily Carter—an industry veteran with over two decades of experience in medical technology—and CFO Michael Liu, a former finance executive at a prominent medtech venture firm, INLIF’s leadership team brings together expertise in device engineering, clinical research, and commercial strategy. The company’s board of directors features seasoned professionals in digital health innovation, supporting its mission to empower patients and providers with intelligent, data-driven care solutions.
AI Generated. May Contain Errors.
